The Non-viral Transfection Reagents and Systems Market is anticipated to grow at a CAGR of ~10% till 2035, claims Roots Analysis

With increasing focus on genetically modified therapies, there is a consequent rise in the demand for efficient gene delivery vectors and innovators are actively evaluating the potential of non-viral transfection agents. Driven by the growing demand for cell and gene therapies, and the ongoing efforts of industry stakeholders, the non-viral transfection reagents and systems market is anticipated to grow at a steady pace in the foreseen future. With increasing focus on genetically modified...

With increasing focus on genetically modified therapies, there is a consequent rise in the demand for efficient gene delivery vectors and innovators are actively evaluating the potential of non-viral transfection agents. Driven by the growing demand for cell and gene therapies, and the ongoing efforts of industry stakeholders, the non-viral transfection reagents and systems market is anticipated to grow at a steady pace in the foreseen future.

To order this 275+ pages report, which features 120+ figures and 140+ tables, please visit the link

Key Market Insights

More than 185 non-viral transfection reagents are being offered by ~55 players

Around 85% of the reagents assist in delivering DNA molecules, while more than 50% reagents are used for the delivery of RNA molecules. Further, it is worth highlighting that ~60% of these transfection reagents use lipids as the preferred carriers for gene delivery.    

Over 20 electroporation-based transfection systems are offered by more than 10 players

Majority of the electroporation-based transfection system providers are headquartered in North America (75%), followed by those based in Asia-Pacific (17%) and Europe (8%). More than 50% of these system providerss were established pre-2000. 

Close to 40 other non-viral transfection systems have been commercialized

More than 90% of the available systems are compatible with human cells and cell lines. Further, more than 65% of these platforms are capable of transfection of both types of molecules (DNA and RNA).

Since 2019, 860+ patents have been filed / granted for non-viral transfection reagents and systems

Close to 70% of the patents are being processed as applications, while around 30% of the total patents filed have been granted. Majority (50%) of the patents have been filed by applicants based in North America.

More than 450 articles focused on non-viral transfection have been published in the recent years

Nearly 70% of the aforementioned publications are research articles, while the remaining are review articles related to the non-viral transfection reagents and systems. Most of the articles were focused on the delivery of DNA molecules via non-viral transfection reagents.

Several big pharma players have undertaken various types of initiatives related to non-viral transfection systems, between 2017 and 2022

Of all the recent big pharma initiatives, close to 80% were collaborations; of these, ~70% were for research and development purposes. Further, ~60% of the initiatives were focused on the development of oncological cell and gene therapies.

North America and Europe are anticipated to capture over 75% of the market share, by 2035

The market in Asia-Pacific and rest of the world is anticipated to grow at a relatively faster pace and occupy ~25% of the total market in 2035. Further, academic and research institutes are making the maximum contribution (over 50%) to the non-viral transfection reagents and systems market, followed by pharma and biotech companies (~45%).  

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The future opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:

The report includes detailed profiles of key players (listed below) engaged in the development of non-viral transfection reagents and systems; each profile features an overview of the developer, financial information (if available), details related to its product portfolio, recent developments, and an informed future outlook:

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/non-viral-transfection/307.html  or email sales@rootsanalysis.com 

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-non-viral-transfection-reagents-and-systems-market-is-anticipated-to-grow-at-a-cagr-of-10-till-2035-claims-roots-analysis-301852169.html